Spectrum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SPPI Spectrum Pharmaceuticals Inc
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
FRST Primis Financial Corp
VII 7GC & Holdings Co Inc
PEBO Peoples Bancorp Inc
BIOAF Bioasis Technologies Inc
NRGOF Newrange Gold Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Closing Price
$0.8198
Day's Change
0.0098 (1.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.83
Day's Low
0.7988
Volume
(Light)
Volume:
1,129,883

10-day average volume:
2,318,281
1,129,883

CDW to Participate in the Credit Suisse 26th Annual Technology Conference

8:00 am ET November 15, 2022 (BusinessWire) Print

CDW Corporation (Nasdaq: CDW), a leading multi-brand provider of information technology solutions to business, government, education and healthcare customers in the United States, the United Kingdom and Canada, today announced that Christine A. Leahy, president and chief executive officer, and Albert J. Miralles, senior vice president and chief financial officer, CDW, will participate in a question and answer session at the Credit Suisse 26th Annual Technology Conference to be held at The Phoenician in Scottsdale, Arizona on Tuesday, November 29, 2022, at 2:00 p.m. CT/1:00 p.m. MT. The session will be webcast live on investor.cdw.com. An archived copy of the webcast will be available on the same website for one year following the completion of the event.

About CDW

CDW Corporation (Nasdaq: CDW) is a leading multi-brand provider of information technology solutions to business, government, education and healthcare customers in the United States, the United Kingdom and Canada. A Fortune 500 company and member of the S&P 500 Index, CDW was founded in 1984 and employs approximately 15,000 coworkers. For the trailing twelve months ended September 30, 2022, CDW generated Net sales of approximately $24 billion. For more information about CDW, please visit www.CDW.com.

CDWPR-FI

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005445/en/

SOURCE: CDW Corporation

Investor Inquiries 
Steven O'Brien
Vice President, Investor Relations
(847) 968-0238
investorrelations@cdw.com 

Media Inquiries 
Sara Granack
Vice President, Corporate Communications
(847) 419-7411
mediarelations@cdw.com
comtex tracking

COMTEX_418924984/1006/2022-11-15T08:00:03

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.